Skip to main content
. Author manuscript; available in PMC: 2014 Jun 14.
Published in final edited form as: J Immunol. 2013 Jun 17;191(2):583–593. doi: 10.4049/jimmunol.1300483

Table II.

CD8+ T cell AV9+ TCR CDR3 diversity

Mouse Strains AV9 Segment Usage CDR3 Diversity
C57BL/6 42/45a
9D-4b 28
9-4 14
A*01:03 28/28
9D-4 14
9N-3 12
9N-4 1
9D-1 1
A*24:02 19/20
9N-2 12
9D-1 5
9N-3 2
B*08:01 27/32
9N-3 17
9D-4 8
9N-4 3
9D-1 3
9N-2 1
B*27:05 36/37
9N-3 21
9D-4 7
9N-4 6
9D-1 2
9D-2 1
B*35:01 20/20
9N-3 12
9N-2 7
9-4 1
B*44:02 19/19
9D-4 11
9N-3 4
9-4 2
9N-2 1
9D-1 1
C*07:01 25/32
9N-3 18
9D-4 10
9D-1 4
9-4 2

After purification of CD8+ T cells, the CDR3 subregions of AV9+ TCR α-chains from each of the HLA monochain transgenic strains were RT-PCR amplified, cloned, and sequenced; AV9+ TCR α-chains of C57BL/6 WT mice were similarly analyzed.

a

Number of different CDR3 sequences versus the total number of in-frame sequences analyzed.

b

Usage of the individual variable segments of the AV9 family.